Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 6/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 5/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.35 |
| ▸ | PFKFB4 | Q16877 | 1/20 | 0.33 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.33 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.33 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.33 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.33 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.33 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 2/20 | 0.32 |
| ▸ | HTR2A | P28223 | 2/20 | 0.32 |
| ▸ | HTR7 | P34969 | 2/20 | 0.32 |
| ▸ | HTR6 | P50406 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4442798 | 0.88 | CMA1 (0.39) | CMA1CA2MTNR1AMTNR1BPFKFB4 | |
| SCHEMBL788282 | 0.77 | CMA1 (0.48) | CMA1PFKFB4DRD2HTR2AHTR7 | |
| SCHEMBL2115426 | 0.72 | CMA1 (0.42) | CMA1PFKFB4 | |
| SCHEMBL7539216 | 0.69 | NPSR1 (0.45) | CMA1CA2PFKFB4HTR6 | |
| SCHEMBL787942 | 0.68 | CMA1 (0.51) | CMA1PFKFB4DRD2HTR2AHTR7 | |
| SCHEMBL1743697 | 0.66 | CMA1 (0.49) | CMA1CA2PFKFB4DRD2HTR2A | |
| SCHEMBL2114201 | 0.66 | MTNR1A (0.52) | CA2MTNR1AMTNR1BHTR2A | |
| SCHEMBL13508283 | 0.63 | CMA1 (0.52) | CMA1PFKFB4DRD2HTR2AHTR7 | |
| SCHEMBL7472162 | 0.63 | NPSR1 (0.45) | CMA1CA2PFKFB4HTR6 | |
| SCHEMBL788489 | 0.63 | PFKFB3 (0.54) | CMA1PFKFB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158655-B2 | Chymase inhibitors; to treat allergic, inflammatory and fibrotic diseases; 5-Fluoro-3-methyl-benzo[b]thiophene-2-sulfonic acid (4-bromo-2-trifluoromethyl-phenyl)-amide | HOFFMANN-LA ROCHE INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-8158655-B2 | Chymase inhibitors; to treat allergic, inflammatory and fibrotic diseases; 5-Fluoro-3-methyl-benzo[b]thiophene-2-sulfonic acid (4-bromo-2-trifluoromethyl-phenyl)-amide | HOFFMANN-LA ROCHE INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-8158655-B2 | Chymase inhibitors; to treat allergic, inflammatory and fibrotic diseases; 5-Fluoro-3-methyl-benzo[b]thiophene-2-sulfonic acid (4-bromo-2-trifluoromethyl-phenyl)-amide | HOFFMANN-LA ROCHE INC. (US) | 2012-04-17 | — | — | US | disclosed |
| EP-2118062-A1 | SULFONAMIDE DERIVATIVES AS CHYMASE INHIBITORS | F. Hoffmann-Roche AG (CH) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008084004-A1 | SULFONAMIDE DERIVATIVES AS CHYMASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-17 | — | — | WO | disclosed |
| WO-2008084004-A1 | SULFONAMIDE DERIVATIVES AS CHYMASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-17 | — | — | WO | disclosed |
| US-20080167348-A1 | NOVEL SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-10 | — | — | US | disclosed |
| US-20080167348-A1 | NOVEL SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-10 | — | — | US | disclosed |
| US-20080167348-A1 | NOVEL SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167348-A1 | NOVEL SULFONAMIDE DERIVATIVES | CMA1, ARSA, TPSAB1 | CMA1 1/4885CA2 17/4885MTNR1A 568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.